zinc finger protein 839 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored ZNF839P1 profile across patient tissues and cancer cell-line models. ZNF839P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZNF839P1 is differentially expressed in 3, with the highest sampling consensus in CHOL. Additionally, ZNF839P1 RNA expression shows 5,589 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight BLCA, CHOL, and HNSC as cancer lineages where ZNF839P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF839P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF839P1 survival associations across molecular data types. ZNF839P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF839P1 RNA expression–survival associations across cancer types. High ZNF839P1 expression shows unfavorable associations in BLCA, TGCT, READ, COAD and THCA, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify BLCA as the clearest survival context for ZNF839P1 RNA expression.
This table summarizes ZNF839P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF839P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF839P1 shows lower tumor expression in KICH and higher tumor expression in CHOL and BRCA. The CHOL box plot shows higher ZNF839P1 RNA expression in tumor versus normal tissue (log2 FC = +0.145, t-test p = .010).
This table shows molecular features associated with ZNF839P1 in patient tissues and cancer cell lines. In patient samples, ZNF839P1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
